Načítá se...
Treatment discontinuation and re-initiation of anti-PD-(L)1 agents in metastatic cancers
INTRODUCTION: Immune checkpoint inhibitors (ICIs) are approved in multiple indications for cancer care. Most of the clinical trials have not questioned shorter than until disease progression approaches. In this study, we present results from a cohort of multiple advanced cancers treated with restric...
Uloženo v:
| Vydáno v: | J Cancer Res Clin Oncol |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer Berlin Heidelberg
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7324422/ https://ncbi.nlm.nih.gov/pubmed/32306129 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00432-020-03217-7 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|